Back to Depression And Anxiety
NCT00366652
NCT00366652
Who may be able to join
Who might be able to join this trial:
- You are a man or woman between 18 and 55 years old
- You are considered healthy based on your medical history, a physical exam, blood/lab tests, vital signs (like blood pressure and heart rate), and a heart tracing test (ECG)
- You have not smoked for at least 1 year
Who may not be able to join:
- No specific exclusion criteria were listed in the provided information (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 3
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Registry
clinicaltrials_gov
Start date
1 September 2006
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
The primary outcome of the study is to evaluate the effects of multiple doses of DVS SR and duloxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.